your market intelligence analyst
Search Results
21 results
Your search is now limited to «Prostate Cancer» expert search. 08/04/2020 07:25
Condition : Castration-Resistant Prostatic Cancer Interventions : Drug: Niraparib; Drug: Abiraterone acetate (AA); Drug: Prednisone; Drug: Placebo for Niraparib Sponsor : Janssen Research & Development, LLC Not yet recruiting.
The androgen receptor (AR) pathway plays a central role in the development of castration-resistant prostate cancer (CRPC). The histone demethylase JMJD1A has been shown to regulate activities of AR and c-Myc transcription factors and promote prostate cancer progression. Here, we report that JMJD1A protein stability is controlled by the ubiquitin ligase STUB1. High levels of JMJD1A were strongly correlated with low STUB1 levels in human CRPC specimens. STUB1 inhibited AR activity, AR-V7 levels, and prostate cancer cell growth partly through degradation of JMJD1A. Furthermore, the acetyltransferase p300 acetylated JMJD1A at lysine (K) 421, a modification that recruits the BET family member BRD4 to block JMJD1A degradation and promote JMJD1A r.
Higher red blood cell and platelet counts were associated with an elevated risk of prostate cancer diagnosis, and higher MCV, MCH, MCHC, and MSCV were associated with a lower risk of prostate cancer diagnosis, but red blood cell and platelet parameters were not associated with prostate cancer mortality.
Purpose:. Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) PTEN, RB1 , and TP53 . Circulating tumor cells (CTC) provide a minimally invasive opportunity for identification and molecular characterization of AVPC. We aimed to evaluate the incidence and clinical significance of compound (2+)TSG losses and genomic instability in prostate cancer CTC, and to expand the set genomic biomarkers relevant to AVPC. Experimental Design:. Genomic analysis of chromosomal copy-number alterations (CNA) at single-cell resolution was performed in CTC from patients with and without AVPC before initiating chemotherapy with ca.
PubMed News (NIH) 08/01/2020
Contributors : Brendon M Patierno ; Wen-Chi Foo ; Tyler Allen ; Jason A Somarelli ; Kathryn E Ware ; Santosh Gupta ; Sandra Wise ; John P Wise ; Xiaodi Qin ; Dadong Zhang ; Lingfan Xu ; Yanjing Li ; Xufeng Chen ; Brant A Inman ; Shannon J McCall ; Jiaoti Huang ; Rick A Kittles ; Kouros Owzar ; Simon Gregory ; Andrew J Armstrong ; Daniel J George ; Steven R Patierno ; David S Hsu ; Jennifer A Freedman Series Type : Expression profiling by high throughput sequencing Organism : Homo sapiens. Here we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease.

Personal Care

Household Products

Business Issues


Companies - Public

Companies - Venture Funded

Information Technologies


Job Titles